iMetabolic Biopharma

iMetabolic Biopharma is a private, pre-revenue biotech founded in 2018, positioning itself at the intersection of artificial intelligence and therapeutic discovery. Its core strategy is to use its proprietary computational iPlatform to design biologics for obesity-related diseases, aiming to overcome traditional drug development inefficiencies. The company has established key strategic partnerships with technology and biopharma entities but remains in the early, non-clinical stage of asset development without a disclosed pipeline.

Proprietary 'iPlatform' using TechBio AI for in-silico therapeutic discovery and molecular design of biologics, aimed at accelerating and reducing the cost of drug development.

iMBP operates in the highly competitive obesity/CVD space, facing off against large pharmaceutical companies and numerous biotechs. It also competes within the broader 'TechBio' or AI-drug discovery sector, where many companies are vying to prove the superiority of their computational platforms.